Home
CANF
CANF News

Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) News on April 3, 2025

ACCESS Newswire

6 days ago

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MT Newswires

10 days ago

Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

GlobeNewswire

10 days ago

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

GlobeNewswire

14 days ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

GlobeNewswire

15 days ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

MT Newswires

16 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

16 days ago

Sector Update: Health Care Stocks Edge Down in Afternoon Trading

MT Newswires

16 days ago

Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

GlobeNewswire

16 days ago

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

GlobeNewswire

a month ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

GlobeNewswire

a month ago

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

GlobeNewswire

2 months ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

GlobeNewswire

2 months ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Can-Fite BioPharma secures US patent for Namodenoson

Pharmaceutical Technology

2 months ago

Can-Fite BioPharma secures US patent for Namodenoson

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

GlobeNewswire

2 months ago

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

Zacks

3 months ago

CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

GlobeNewswire

3 months ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

Zacks

4 months ago

Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

GlobeNewswire

4 months ago

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

4 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MT Newswires

5 months ago

Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

GlobeNewswire

5 months ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Secures Australian Patent for Obesity Drug

TipRanks

5 months ago

Can-Fite BioPharma Secures Australian Patent for Obesity Drug

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

GlobeNewswire

5 months ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

MT Newswires

6 months ago

Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

GlobeNewswire

6 months ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

MT Newswires

6 months ago

Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer

GlobeNewswire

6 months ago

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

GlobeNewswire

6 months ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

GlobeNewswire

6 months ago

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

GlobeNewswire

7 months ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?

Insider Monkey

7 months ago

Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

GlobeNewswire

7 months ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

8 months ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

GlobeNewswire

8 months ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

GlobeNewswire

8 months ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8

GlobeNewswire

9 months ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8

GlobeNewswire

9 months ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

GlobeNewswire

9 months ago

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix

Business Wire

9 months ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Business Wire

9 months ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Business Wire

10 months ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

10 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

10 months ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

10 months ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

10 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Simply Wall St.

10 months ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Simply Wall St.

10 months ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

AFP

10 months ago

Seoul resumes loudspeaker propaganda against North

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Business Wire

10 months ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Business Wire

10 months ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Business Wire

10 months ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6

Business Wire

10 months ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Business Wire

a year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial

Clinical Trials Arena

a year ago

Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Business Wire

a year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Business Wire

a year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

ACCESSWIRE

a year ago

Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Business Wire

a year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Business Wire

a year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Business Wire

a year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Newsfile

a year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Business Wire

a year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Business Wire

a year ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Business Wire

a year ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

AmpliTech Continues Its New Products Rollout, Featuring The Latest Products In 5G And SATCOM At The MWC Show in Barcelona and Satellite Show in Washington DC

GlobeNewswire

a year ago

AmpliTech Continues Its New Products Rollout, Featuring The Latest Products In 5G And SATCOM At The MWC Show in Barcelona and Satellite Show in Washington DC

$MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

GlobeNewswire

a year ago

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Business Wire

a year ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Business Wire

a year ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

GlobeNewswire

a year ago

INFINT Acquisition Corporation Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public Shareholders

Local Bounti Amends Cargill Credit Facility and Receives Funds for Working Capital

PR Newswire

a year ago

Local Bounti Amends Cargill Credit Facility and Receives Funds for Working Capital

BurgerFi Shouts "Yes, Chef" With All-New Burger

PR Newswire

a year ago

BurgerFi Shouts "Yes, Chef" With All-New Burger

Hear from BODi Exec Chairman Mark Goldston, CEO Carl Daikeler Live at ICR Conference

Exec Edge

a year ago

Hear from BODi Exec Chairman Mark Goldston, CEO Carl Daikeler Live at ICR Conference

2024’s Underdog Tech Stocks: 3 Hidden Gems in a Crowded Market

InvestorPlace

a year ago

2024’s Underdog Tech Stocks: 3 Hidden Gems in a Crowded Market

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

GlobeNewswire

a year ago

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

GlobeNewswire

a year ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Business Wire

a year ago

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

GlobeNewswire

a year ago

Inno Holdings Inc. Announces Closing of $10,000,000 Initial Public Offering

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Business Wire

a year ago

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

GlobeNewswire

a year ago

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

ACCESSWIRE

a year ago

INNO Holdings Launches Innovative Mobile Factory: Reinventing Construction Efficiency with Onsite Steel Framing Production

ACCESSWIRE

a year ago

Inno Holdings Paves the Way for Sustainable Construction: Championing Green Building with Cold-Formed Steel

ACCESSWIRE

a year ago

Inno Holdings Commences Trading on Nasdaq Capital Market

Steel Connect Reports First Quarter Fiscal 2024 Financial Results

Business Wire

a year ago

Steel Connect Reports First Quarter Fiscal 2024 Financial Results

An Intrinsic Calculation For Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Suggests It's 29% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Suggests It's 29% Undervalued

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Zacks

a year ago

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Beamr Releases White Paper on using its CABR Solution to Boost Vision AI

GlobeNewswire

a year ago

Beamr Releases White Paper on using its CABR Solution to Boost Vision AI

Meta Materials Releases Board Letter to Shareholders

ACCESSWIRE

a year ago

Meta Materials Releases Board Letter to Shareholders

Gaia Appoints James Colquhoun as CEO and Launches New AI Powered Search

GlobeNewswire

a year ago

Gaia Appoints James Colquhoun as CEO and Launches New AI Powered Search

Jacobs leading takeover of software company as he readies next move

FreightWaves

a year ago

Jacobs leading takeover of software company as he readies next move

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Business Wire

a year ago

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

PR Newswire

a year ago

KLX Energy Services to Present at Sidoti Small Cap Conference on December 6th

OSS Appoints Technology and Defense Industry Executive, Mitchell H. Herbets, to Board of Directors

GlobeNewswire

a year ago

OSS Appoints Technology and Defense Industry Executive, Mitchell H. Herbets, to Board of Directors

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Business Wire

a year ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

KLX Energy Services Holdings, Inc. (NASDAQ:KLXE) most popular amongst individual investors who own 40% of the shares, institutions hold 30%

Simply Wall St.

a year ago

KLX Energy Services Holdings, Inc. (NASDAQ:KLXE) most popular amongst individual investors who own 40% of the shares, institutions hold 30%

Investors Will Want Harte Hanks' (NASDAQ:HHS) Growth In ROCE To Persist

Simply Wall St.

a year ago

Investors Will Want Harte Hanks' (NASDAQ:HHS) Growth In ROCE To Persist

Is It Smart To Buy LCNB Corp. (NASDAQ:LCNB) Before It Goes Ex-Dividend?

Simply Wall St.

a year ago

Is It Smart To Buy LCNB Corp. (NASDAQ:LCNB) Before It Goes Ex-Dividend?

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

Zacks

a year ago

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

Share on Social Networks: